eyeball

eyeball2

eyeball3

eyeball4

Study Overview

Wet age-related macular degeneration (wAMD) is a leading cause of vision loss in individuals age 50 years or older. This study explores an investigational drug named EYP-1901 that is designed to potentially block the proteins that cause wAMD. This study is investigating the study drug (EYP-1901) to find out how safe and effective it is compared to aflibercept (an approved treatment for individuals with wAMD). This clinical research study will help researchers learn:

How safe EYP-1901 is compared to aflibercept
How effective EYP-1901 is compared to aflibercept

Who Can Join!

To participate in the LUGANO clinical research study, you must:

Be at least 50 years of age or older
Be diagnosed with wAMD
Not have had cataract surgery in the last 12 weeks
Not have had corneal transplant surgery

This is not a complete list of study requirements. The study doctor will review the full requirements for this study with you.

What to Expect?

You will be in this clinical research study approximately 99 weeks (about 2 years), and you will be asked to visit the study center at least 14 times over this period. Laboratory tests, eye examinations, and other assessments will be conducted as part of this study.